Creatinine Test Market is Expected to Grow with a CAGR of 16.1% from 2022 to 2028

Creatinine Test
  • Creatinine Test Market

As stated in our extensive report, theGlobalCreatinine Test Marketaccounted forUSD 995.1 Millionin 2021.

Creatinine is defined as a waste product or a chemical compound leftover from energy-producing processes in the muscles. If the kidneys are healthy, they filter out the creatinine of the blood. It exists in the urine as a waste product. A creatinine test helps to find if the kidneys are performing well and filtering waste from the blood or not. Measurement of creatinine in the blood or urine helps the doctor to determine how well the kidneys are working. Creatinine most of the time enters the bloodstream and is filtered from the bloodstream at a usually constant rate. The amount of creatinine in one’s blood should be relatively stable and if it is been increased compared to the normal level then it may be a sign of poor kidney function. The normal creatinine level is mostly dependent on measures such as serum creatinine level, glomerular filtration rate (GFR), creatinine clearance, and albumin/creatinine ratio.

The increasing prevalence of kidney disorders across the globe is anticipated to augment the growth of the Creatinine Test Market in the years to come. When people suffer from chronic kidney disease, their kidneys are damaged and with time they may not clean the blood as well as healthy kidneys. If kidneys stop functioning properly, the toxic waste and extra fluid keeps on accumulating inside the body and lead to heart disease, high blood pressure, stroke, and even early death. However, people at risk for CKD can take preventive measures to protect their kidneys with the help of proper consultants. As per the Centers for Disease Control and Prevention, more than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have CKD. It is also estimated that CKD is more common in a person aged 65 years or older that is almost 38% than in people aged 45–64 years (12%) or 18–44 years (6%) and CKD is slightly more common in women (14%) than men (12%). This in turn is expected to increase the demand for creatinine test in the years to come. Furthermore, the increasing demand for rapid and easy-to-use urine tests and the growing diagnostics segment is also expected to support the growth of the market in near future.

However, the lack of predictive value obtained by creatinine tests and frequently changing regulatory policies is expected to hamper the growth of the market in the years to come. Moreover, the commercialization of advanced testing methods along with an increase in investments is further expected to augment the growth of the market within the forecast period. Additionally, the favorable government initiatives to promote renal health are also expected to support the growth of the market.

North America held the largest share in the Global Creatinine Test Market and is likely to continue the same trend during the forecast period. The U.S. dominated in the North America region.This is attributable to the favorable reimbursement policies & government initiatives in the region. Additionally, the easy availability of technologically advanced products and well-established healthcare infrastructure is also supporting the growth of the Creatinine Test Market in the region.Asia Pacific is expected to grow at the fastest CAGR during the forecast period. This is attributable to the rapid growth in the geriatric population along with an increase in investments by leading market players in emerging economies like India, and China in the region. Furthermore, the growing awareness and adoption of preventive healthcare are also anticipated to support the regional growth of the market.

Some of the prominent players operating in the GlobalCreatinine Test Market include BioAssay Systems, Abcam plc, Arbor Assays, Thermo Fisher Scientific, Randox Laboratories Ltd., Sentinel CH. SpA, DiaSys Diagnostic Systems GmbH, MedTest Holdings, Inc. (Pointe Scientific, Inc.), Abbexa Ltd., and General Atomics, Inc. (Diazyme Laboratories, Inc.)..